基础慢性肝脏疾病对接受免疫检查点抑制剂治疗的肿瘤患者的疗效及安全性的影响

刘丹; 姚甜甜; 张宇涵; 王贵强; 王艳

doi:10.3969/j.issn.1001-5256.2022.11.005

基础慢性肝脏疾病对接受免疫检查点抑制剂治疗的肿瘤患者的疗效及安全性的影响

DOI: 10.3969/j.issn.1001-5256.2022.11.005

北京大学第一医院感染疾病科，北京 100034

基金项目:

国家十三五重大课题 (2017ZX10203202-002-012);

国家十三五重大课题 (2018ZX10302206-001-007);

国家自然科学基金 (81870417);

国家自然科学基金 (82070605)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：刘丹、姚甜甜、张宇涵负责查找文献，分析资料；刘丹、姚甜甜负责撰写和修改文稿；王贵强负责文章思路指导；王艳负责确定写作思路，指导文章撰写及最终定稿。

详细信息

通信作者:
王艳，wangyanwang@bjmu.edu.cn

作者说明：刘丹和姚甜甜对本文贡献等同，为共同第一作者

计量
- 文章访问数: 618
- HTML全文浏览量: 132
- PDF下载量: 84
- 被引次数: 0
出版历程
- 收稿日期: 2022-06-19
- 录用日期: 2022-07-25
- 出版日期: 2022-11-20

Efficiency and safety of immune checkpoint inhibitors in cancer patients with chronic liver disease: A systematic review

Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China

Research funding:

The Sub-Subject of the Major Projects of National Science and Technology (2017ZX10203202-002-012);

The Sub-Subject of the Major Projects of National Science and Technology (2018ZX10302206-001-007);

National Natural Science Foundation of China (81870417);

National Natural Science Foundation of China (82070605)

More Information

Corresponding author: WANG Yan, wangyanwang@bjmu.edu.cn(ORCID: 0000-0002-8577-0527)

摘要

摘要: 近年来免疫检查点抑制剂(ICI)已经被批准用于多种恶性肿瘤的治疗，与此同时，接受ICI治疗且具有慢性肝脏疾病背景的肿瘤人群大幅增加。慢性肝脏疾病是否影响ICI的疗效和安全性逐渐成为热点问题。本文简要概述合并不同类型慢性肝脏疾病(慢性病毒性肝炎、非酒精性脂肪性肝病、自身免疫性肝病、肝硬化等)基础的肿瘤(原发性肝癌、非小细胞肺癌、黑色素瘤)患者应用ICI的有效性和安全性，并对慢性乙型肝炎患者ICI治疗后HBV再激活的相关文献进行综述，以期对存在慢性肝脏疾病基础的肿瘤患者ICI使用诊疗规范的制订和完善提供依据。
- 肝疾病 /
- 肿瘤 /
- 免疫检查点抑制剂 /
- 乙型肝炎
Abstract: Immune checkpoint inhibitors (ICIs) have recently been approved for the treatment of cancer, and the number of cancer patients with chronic liver disease (CLD) receiving ICIs is growing rapidly. However, whether CLD affects the efficiency and safety of ICIs is becoming a research focus. This review summarizes the efficiency and safety of ICIs in cancer patients with CLD, including chronic viral hepatitis, non-alcoholic fatty liver disease, autoimmune liver disease, and cirrhosis. Specifically, data on hepatitis B virus reactivation of patients with chronic hepatitis B after ICIs treatment were reviewed, which may help to perfect and standardize the guidelines of treatment and following-up for ICIs in CLD patients.
- Liver Diseases /
- Neoplasms /
- Immune Checkpoint Inhibitors /
- Hepatitis B

HTML全文

参考文献(39)

[1]	BAGCHI S, YUAN R, ENGLEMAN EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance[J]. Annu Rev Pathol, 2021, 16: 223-249. DOI: 10.1146/annurev-pathol-042020-042741.
[2]	KUMAR V, CHAUDHARY N, GARG M, et al. Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAE) induced by immune checkpoint inhibitor therapy[J]. Front Pharmacol, 2017, 8: 311. DOI: 10.3389/fphar.2017.00311.
[3]	ZEN Y, YEH MM. Checkpoint inhibitor-induced liver injury: A novel form of liver disease emerging in the era of cancer immunotherapy[J]. Semin Diagn Pathol, 2019, 36(6): 434-440. DOI: 10.1053/j.semdp.2019.07.009.
[4]	XIAO J, WANG F, WONG NK, et al. Global liver disease burdens and research trends: Analysis from a Chinese perspective[J]. J Hepatol, 2019, 71(1): 212-221. DOI: 10.1016/j.jhep.2019.03.004.
[5]	EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
[6]	General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. J Clin Hepatol, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009. 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 临床肝胆病杂志, 2022, 38(2): 288-303. DOI: 10.3969/j.issn.1001-5256.2022.02.009.
[7]	YAU T, HSU C, KIM TY, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis[J]. J Hepatol, 2019, 71(3): 543-552. DOI: 10.1016/j.jhep.2019.05.014.
[8]	PU D, YIN L, ZHOU Y, et al. Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review[J]. Medicine (Baltimore), 2020, 99(5): e19013. DOI: 10.1097/MD.0000000000019013.
[9]	PAN S, YU Y, WANG S, et al. Correlation of HBV DNA and hepatitis B surface antigen levels with tumor response, liver function and immunological indicators in liver cancer patients with hbv infection undergoing PD-1 inhibition combinational therapy[J]. Front Immunol, 2022, 13: 892618. DOI: 10.3389/fimmu.2022.892618.
[10]	NG K, WONG L, ANG A, et al. Real-world efficacy and safety of immune checkpoint inhibitors in advanced hepatocellular carcinoma: Experience of a tertiary Asian Center[J]. Asia Pac J Clin Oncol, 2021, 17(5): e249-e261. DOI: 10.1111/ajco.13454.
[11]	ALKREKSHI A, TAMASKAR I. Safety of immune checkpoint inhibitors in patients with cancer and hepatitis C virus infection[J]. Oncologist, 2021, 26(5): e827-e830. DOI: 10.1002/onco.13739.
[12]	SHAH NJ, AL-SHBOOL G, BLACKBURN M, et al. Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection[J]. J Immunother Cancer, 2019, 7(1): 353. DOI: 10.1186/s40425-019-0771-1.
[13]	BRAHMER J, RECKAMP KL, BAAS P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(2): 123-135. DOI: 10.1056/NEJMoa1504627.
[14]	BORGHAEI H, PAZ-ARES L, HORN L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer[J]. N Engl J Med, 2015, 373(17): 1627-1639. DOI: 10.1056/NEJMoa1507643.
[15]	XU F, ZENG Z, YAN B, et al. Safety and efficacy of anti-PD-1 inhibitors in Chinese patients with advanced lung cancer and hepatitis B virus infection: a retrospective single-center study[J]. Transl Lung Cancer Res, 2021, 10(4): 1819-1828. DOI: 10.21037/tlcr-21-79.
[16]	PERTEJO-FERNANDEZ A, RICCIUTI B, HAMMOND SP, et al. Safety and efficacy of immune checkpoint inhibitors in patients with non-small cell lung cancer and hepatitis B or hepatitis C infection[J]. Lung Cancer, 2020, 145: 181-185. DOI: 10.1016/j.lungcan.2020.02.013.
[17]	HODI FS, O'DAY SJ, MCDERMOTT DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med, 2010, 363(8): 711-723. DOI: 10.1056/NEJMoa1003466.
[18]	RAVI S, SPENCER K, RUISI M, et al. Ipilimumab administration for advanced melanoma in patients with pre-existing hepatitis B or C infection: a multicenter, retrospective case series[J]. J Immunother Cancer, 2014, 2(1): 33. DOI: 10.1186/s40425-014-0033-1.
[19]	WEN X, WANG Y, DING Y, et al. Safety of immune checkpoint inhibitors in Chinese patients with melanoma[J]. Melanoma Res, 2016, 26(3): 284-289. DOI: 10.1097/CMR.0000000000000256.
[20]	LEE PC, CHAO Y, CHEN MH, et al. Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. J Immunother Cancer, 2020, 8(2). DOI: 10.1136/jitc-2020-001072.
[21]	ZHANG X, ZHOU Y, CHEN C, et al. Hepatitis B virus reactivation in cancer patients with positive Hepatitis B surface antigen undergoing PD-1 inhibition[J]. J Immunother Cancer, 2019, 7(1): 322. DOI: 10.1186/s40425-019-0808-5.
[22]	YOO S, LEE D, SHIM JH, et al. Risk of hepatitis B virus reactivation in patients treated with immunotherapy for anti-cancer treatment[J]. Clin Gastroenterol Hepatol, 2022, 20(4): 898-907. DOI: 10.1016/j.cgh.2021.06.019.
[23]	DING ZN, MENG GX, XUE JS, et al. Hepatitis B virus reactivation in patients undergoing immune checkpoint inhibition: systematic review with meta-analysis[J]. J Cancer Res Clin Oncol, 2022. DOI: 10.1007/s00432-022-04133-8.
[24]	IOANNOU GN. Epidemiology and risk-stratification of NAFLD-associated HCC[J]. J Hepatol, 2021, 75(6): 1476-1484. DOI: 10.1016/j.jhep.2021.08.012.
[25]	DE OLIVEIRA S, HOUSERIGHT RA, GRAVES AL, et al. Metformin modulates innate immune-mediated inflammation and early progression of NAFLD-associated hepatocellular carcinoma in zebrafish[J]. J Hepatol, 2019, 70(4): 710-721. DOI: 10.1016/j.jhep.2018.11.034.
[26]	PFISTER D, NU'ÑEZ NG, PINYOL R, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC[J]. Nature, 2021, 592(7854): 450-456. DOI: 10.1038/s41586-021-03362-0.
[27]	KICHENADASSE G, MINERS JO, MANGONI AA, et al. Association between body mass index and overall survival with immune checkpoint inhibitor therapy for advanced non-small cell lung cancer[J]. JAMA Oncol, 2020, 6(4): 512-518. DOI: 10.1001/jamaoncol.2019.5241.
[28]	CORTELLINI A, BERSANELLI M, BUTI S, et al. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable[J]. J Immunother Cancer, 2019, 7(1): 57. DOI: 10.1186/s40425-019-0527-y.
[29]	WANG Z, AGUILAR EG, LUNA JI, et al. Paradoxical effects of obesity on T cell function during tumor progression and PD-1 checkpoint blockade[J]. Nat Med, 2019, 25(1): 141-151. DOI: 10.1038/s41591-018-0221-5.
[30]	ZHOU J, ZHOU F, CHU X, et al. Non-alcoholic fatty liver disease is associated with immune checkpoint inhibitor-based treatment response in patients with non-small cell lung cancer with liver metastases[J]. Transl Lung Cancer Res, 2020, 9(2): 316-324. DOI: 10.21037/tlcr.2020.04.15.
[31]	BESSONE F, DIRCHWOLF M, RODIL MA, et al. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view[J]. Aliment Pharmacol Ther, 2018, 48(9): 892-913. DOI: 10.1111/apt.14952.
[32]	SAWADA K, HAYASHI H, NAKAJIMA S, et al. Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor[J]. J Gastroenterol Hepatol, 2020, 35(6): 1042-1048. DOI: 10.1111/jgh.14889.
[33]	ZHANG X, YANG H, ZENG S, et al. Melanoma differentiation-associated gene 5 protects against NASH in mice[J]. Hepatology, 2022, 75(4): 924-938. DOI: 10.1002/hep.32139.
[34]	MCQUADE JL, DANIEL CR, HESS KR, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis[J]. Lancet Oncol, 2018, 19(3): 310-322. DOI: 10.1016/S1470-2045(18)30078-0.
[35]	DE MARTIN E, MICHOT JM, PAPOUIN B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors[J]. J Hepatol, 2018, 68(6): 1181-1190. DOI: 10.1016/j.jhep.2018.01.033.
[36]	MENZIES AM, JOHNSON DB, RAMANUJAM S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab[J]. Ann Oncol, 2017, 28(2): 368-376. DOI: 10.1093/annonc/mdw443.
[37]	BHAVE P, PHAM A, GORDON A, et al. Safe administration of anti-PD-1 immunotherapy in a patient with pre-existing primary biliary cholangitis[J]. Immunotherapy, 2020, 12(7): 445-450. DOI: 10.2217/imt-2019-0184.
[38]	KUDO M, MATILLA A, SANTORO A, et al. Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status[J]. J Clin Oncol, 2019, 37: 327.
[39]	LEE PC, CHAO Y, CHEN MH, et al. Predictors of response and survival in immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma[J]. Cancers (Basel), 2020, 12(1): 182. DOI: 10.3390/cancers12010182.